New findings show metabolic changes suggesting that a carbohydrate-restricted diet may improve insulin sensitivity.
Researchers find 23% increased risk compared to men who received other treatments.
Adding bevacizumab to androgen deprivation therapy (ADT) resulted in improved relapse-free survival in patients with hormone-sensitive prostate cancer.
The advice is useful as clinicians wait for formal guidelines.
Combined radiotherapy remains controversial due to the increased potential for toxicities.
Anti-androgen therapy during and after salvage radiotherapy in patients with localized prostate cancer significantly improved long-term overall survival.
The finding of lower bladder cancer incidence in patients receiving pelvic radiation contrasts with previous research.
In a small study, high-dose testosterone given intermittently with androgen deprivation therapy lowered PSA levels without serious adverse effects.
A 12-gene androgen deprivation therapy resistance signature may help guide therapeutic decision making after radical prostatectomy.
Higher risks of several clinically relevant adverse effects compared with surgical castration.
The study found no association with obesity, however, unlike previous studies.
A new study by University of Pennsylvania and Stanford researchers highlights a possible link between men who receive androgen deprivation therapy (ADT) and the future onset of Alzheimer's disease.
The risk is highest among patients who switch from anti-androgen to GnRH agonist therapy.
The time to PSA progression in men with relapsing or locally advanced PCa was similar with intermittent and continuous androgen deprivation.
Compared with combination treatment, radiation therapy alone was linked with 64% and 83% lower odds of early death and death from cardiac causes among patients with co-existing illnesses.
This approach is, or should be, the standard of care for locally advanced PCa, some researchers say.
Additional novel medical therapies to treat prostate cancer and earlier use of the existing medical therapies are the future of prostate cancer management.
No residual tumor was found in 5.4% of men who received androgen deprivation therapy prior to radical surgery for high-risk prostate cancer.
Acupuncture's ability to stimulate endorphin production may partly explain the clinical improvements.
Adding chemotherapy to hormone therapy added 14 months to patients' lives in study.
Patients with longer life expectancy are most at risk of cardiac morbidity, researchers concluded.
Many men with low-risk disease being spared prostatectomy, radiation, and androgen deprivation treatment.
Researchers observed greater incidences of colorectal cancer among patients who underwent bilateral orchiectomy, surgery, and ADT.
Researchers observed increases in components of metabolic syndrome and in the prevalence of full metabolic syndrome among men with prostate cancer treated with ADT.
Findings among men treated for localized prostate cancer.
The combination improved oncologic control better than dose-escalated radiotherapy alone in men with intermediate-risk prostate cancer.
Men with a particular gene mutation affected most, researchers find.
This effect appears to occur mainly in men who experience recurrence when they are younger than 65 and in those with low-risk cancer.
Prostate cancer remained stable for an average 10 extra months in men taking statins, but more trials are needed to confirm benefits, researchers say.
Prolonged androgen deprivation treatment ups risk in older men with prostate cancer, especially those with comorbidities.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)